

GW9662

Catalog No: tcsc1102



Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

22978-25-2

Formula:

$C_{13}H_9ClN_2O_3$

Pathway:

Cell Cycle/DNA Damage

Target:

PPAR

Purity / Grade:

>98%

Solubility:

DMSO : ≥ 100 mg/mL (361.43 mM); H₂O :

Observed Molecular Weight:

276.68


Product Description

GW9662 is a potent and selective **PPAR γ** antagonist with an **IC₅₀** of 3.3 nM, showing 10 and 1000-fold selectivity over PPAR α and PPAR δ , respectively.

IC50 & Target: IC50: 3.3 nM/32 nM/2 μ M (PPAR γ / α / δ)^[1]

In Vitro: GW9662 inhibits radioligand binding to PPAR γ , PPAR α , and PPAR δ with pIC₅₀s of 8.48 \pm 0.27 (IC₅₀=3.3 nM; n=10), 7.49 \pm 0.17 (IC₅₀=32 nM; n=9), and 5.69 \pm 0.17 (IC₅₀=2000 nM; n=3), respectively. GW9662 has nanomolar IC₅₀ versus PPAR γ and is 10- and 600-fold less potent in binding experiments using PPAR α and PPAR δ , respectively. In cell-based reporter assays, GW9662 is a potent and selective antagonist of full-length PPAR γ ^[1]. Co-treatment with both 50 μ M Rosiglitazone and 10 μ M GW9662 results in statistically lower viable cell numbers after 7 days when compared to treatment with either 50 μ M rosiglitazone (P=0.001) or 10 μ M GW9662 (P=0.01) alone^[2].

In Vivo: Bone marrow (BM) nucleated cell counts in both BADGE- and GW9662(1 mg/kg, i.p.)-treated mice are significantly higher than counts in the aplastic anemia (AA) group^[3]. GW9662 (1 mg/kg, i.p.) largely attenuates the renoprotective effects of Lipopolysaccharide (LPS) in the rat^[4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!